Clarisa Beatriz Palatnik de Sousa

ORCID:

não disponível no Lattes


Formação:

  • Universidade Federal do Rio de Janeiro

    Ciências (Microbiologia) | Doutorado | 1985 - 1989

  • The Weizman Institute Of Science

    Research Student Biophysics Department | Especialização | 1984 - 1984

  • Universidade Federal do Rio de Janeiro

    Ciências (Microbiologia) | Mestrado | 1981 - 1983

  • The Hebrew University Of Jerusalem Israel

    Bachelor Of Science In Biology | Graduação | 1977 - 1980
Laboratórios:
Nuvens de Palavras:
Artigos:

(50.00% artigos com DOI)

Titulo DOI Ano
'CD4 + Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis' 10.3389/fimmu.2024.1277557 2024
A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron 10.1038/s41598-022-21207-2 2022
Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8High T Cells Are Associated With the Cure of Human Visceral Leishmaniasis 10.3389/fimmu.2021.773983 2021
The delay in the licensing of Protozoal Vaccines: a comparative history 10.3389/fimmu.2020.00204 2020
Portrait of an ISV fellow Clarisa Beatriz Palatnik de Sousa 10.1080/21645515.2020.1748493 2020
What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist 10.3389/fimmu.2020.02173 2020
The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice 10.3389/fimmu.2019.00724 2019
Nucleoside hydrolase NH 36: a vital enzyme for the Leishmania genus in the development of T-cell epitope cross-protective vaccines 2019
Prevalence of IgG Autoantibodies against GD3 Ganglioside in Acute Zika Virus Infection 10.3389/fmed.2018.00025 2018
Editorial: Epitope Discovery and Synthetic Vaccine Design 10.3389/fimmu.2018.00826 2018
NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis 10.3389/fimmu.2018.00967 2018
Dependency of B-1 Cells in the Maintenance of Splenic Interleukin-10 Producing Cells and Impairment of Macrophage Resistance in Visceral Leishmaniasis 10.3389/fmicb.2017.00978 2017
A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection 10.3389/fimmu.2017.00100 2017
Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis 10.3389/fimmu.2017.00227 2017
F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis 10.3389/fimmu.2017.00750 2017
Expression of leukosialin (CD43) defines a major intrahepatic T cell subset associated with protective responses in visceral leishmaniasis 10.1186/s13071-015-0721-9 2015
Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro 10.1371/journal.pone.0124183 2015
Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice 10.1371/journal.pone.0128785 2015
Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis 10.1371/journal.pntd.0004297 2015
Editorial: Preventive Vaccination 10.1016/j.provac.2015.05.001 2015
Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection 10.3389/fimmu.2014.00273 2014
Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains 10.3389/fimmu.2014.00189 2014
The adjuvanticity of Chiococca alba saponins increases with the length and hydrophilicity of their sugar chains 10.1016/j.vaccine.2012.03.006 2012
Vaccines for Canine Leishmaniasis 10.3389/fimmu.2012.00069 2012
Kinetics and Docking Studies of two potential new inhibitors of the Nucleoside Hydrolase from Leishmania donovani 10.1016/j.ejmech.2012.07.052 2012
Resistance to visceral leishmaniasis is severely compromised in mice deficient of Bradykinin B2-Receptors 10.1186/1756-3305-5-261 2012
The Role of Small Companion Animals in Transmission of Emerging Zoonotic Infectious Disease: The Need for a Global Surveillance Strategy. Impact factor ISI 6,169 10.3201/eid1812.120664 2012
One Health: the Global Challenge of Epidemic and Endemic Leishmaniasis. 10.1186/1756-3305-4-197 2011
Immunotherapy with the saponin enriched-Leishmune® vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis 10.1016/j.vaccine.2009.09.071 2010
A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titers in mice. 10.1016/j.vaccine.2010.07.017 2010
'Adaptive Immunity against Leishmania Nucleoside Hydrolase Maps its C-Terminal Domain as the Target of the CD4+ T Cell Driven Protective Response 10.1371/journal.pntd.0000866 2010
: DECREASE OF THE INCIDENCE OF HUMAN AND CANINE VISCERAL LEISHMANIASIS AFTER DOG VACCINATION WITH LEISHMUNE® IN BRAZILIAN ENDEMIC AREAS 10.1016/j.vaccine.2009.03.045 2009
Review a convite:Vaccines for leishmaniasis in the fore coming 25 years 10.1016/j.vaccine.2008.01.023 2008
Review a convite:The FML-vaccine against canine visceral leishmaniasis from the second generation to the synthetic vaccine. 10.1586/14760584.7.6.833 2008
IMMUNOGENICITY ASSAY OF THE LEISHMUNE ® VACCINE AGAINST CANINE VISCERAL LEISHMANIASIS IN BRAZIL 10.1016/j.vaccine.2008.07.029 2008
Assessment of the monoterpene, glycidic and triterpene-moieties´ contributions to the adjuvant function of the CP05-saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis? 2007
Safety trial using the Leishmune ® vaccine against canine visceral leishmaniasis in Brazil 2007
Immunotherapy against experimental canine visceral leishmanasis with the saponin enriched-Leishmune(R) vaccine 10.1016/j.vaccine.2007.06.005 2007
The FML vaccine (Leishmune (R)) against canine visceral leishmaniasis: a transmission blocking vaccine. 2006
Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis 2006
Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani. 2006
Pulcherrima saponin, from the leaves of Calliandra pulcherrima, as adjuvant for visceral leishmaniasis 2005
Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis 2005
Leishmune (R) vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmani parasites in blood, skin and lymph nodes of vaccinated exposed dogs. 2005
The FMLK vaccine (Leishmune (R) agaisnt canine visceral leishmaniasis: A transmission blocking vaccine 2005
Effective immunotherapy against canine visceral leishmaniasis 2004
Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapongenins 2004
Improving methods for epidemiological control of canine visceral leishmaniaiss based on a mathematical model. Impact on the incidence of the canine and human disease 2004
IgG1/IgG2 antibody dichotomy in sera of vccinated or naturally infected dogs with visceral leihmaniosis 2003
Immunotherapy against murine experimental visceral leishmaniasis with the FMLvaccine 2003
Nucleoside Hydrolase from Leishmania donovani is ana antigen diagnostic for visceral leishmaniasis 10.1016/S0166-6851(02)00010-5 2002
Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN) 2002
Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis 2002
What is the potential use of serological tools in diagnosis of human kala-azar? (ananlysis of specificity, sensitivity and predictive values) 2002
Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani 2001
Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil 2001
Visvceral leishmaniasis: circulating Leishmania donovani parasites in blood of infected hamsters. 2001
Occurrence of Leishmani donovani DNA in seroreactive Brazilian blood donors 2000
A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in ana endemic area of Brazil (São Gonçalo do Amaranto,RN) 10.1016/S0264-410X(00)00339-X 2000
Vaccination With The Fml Antigen(Fucose Mannose Ligand Of Leishmania Donovani In The Swiss Albino Model. Comparison Between The Freund Incomplete, Alumina And Saponins Adjuvant Activitites 1999
The FML-ELISA assay in diagnosisi and prognosis of canine visceral leishmaniasis. 1999
Prevalence Of Anti-Leishmania Donovani Antibody Among Brazilian Blood Donnors And Multiply Transfused Hemodyalisis Patients 1997
Haemolytic Activitites Of Plant Saponins And Adjuvants. Effect Of Periandra Mediterranea Saponin On The Humoral Response To The Fml Antigen Of Leishmania Donovani 1997
The Fml (Fucose Mannose Ligand) Of Leishmania Donovani. A New Tool In Diagnosisi, Prognosisi, Transfusional Control And Vaccination Against Human Kala-Azar 1996
Transmission Of Visceral Leishmaniasis By Blood Transfusion In Hamsters 1996
Leishmania Donovani: Titration Of Antibodies To The Fucoes Mannose Ligand As An Aid In Diagnosisi And Prognosis Of Visceral Leishmaniasis 1995
An Improved Method For The Isolation Of Erythrocyte Antigen Band 3 1995
Antigenicity Of Cystatin- Binding Proteins From Parasitic Protozoan: Detection By A Protease-Inhibitor Based Capture Immunoassay (Pinc Elisa) 1995
Experimental Murine Leishmani Donovani Infection: Immunoprotection By The Fucose Mannose Ligand (Fml). 1994
The Fml Vaccine (Fucose-Mannose Ligand) Protects Hamsters From Experimental Kala-Azar 1994
Leishmania Donovani Surface Glycoprotein Gp36, Is The Major Immunogen Component Of The Fucose Mannose Ligand (Fml). 10.1016/0001-706X(93)90006-W 1993
A New Approach To Phylogeny Of Leishmania: Species-Specificity Of Glycoconjugate Ligands For Promastigote Internalization Into Murine Macrophages 1990
Inhibition Of Leishmania Donovani Internalitaziton Into Murine Macrophages By Chemically Defined Parasite Glycoconjugate Ligands 1989
Actividad Grupoespecifica Nssu de Las Sialoglicoproteinas de La Membrana Eritrocitaria 1989
Leptomonas Samueli Glycoconjugates Comparison With Herpetomonas Samuelpessoai 1987
Partial Chemical Characterization Of The Carbohydrate Moieties In Leishmania Adleri Glycoconjugates 1985
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
Otimização da resposta imune vacinal utilizando a quimera recombinante F1F3 contra a leishmaniose visceral murina. 2022
Método imunoinformático como ferramenta na predição de vacina multicepas e multiepítopos de SARS-CoV-2 segura contra trombose trombocitopênica pós-vacinal. 2022
. Análise de homologia das proteínas S, E, M e N de cada variante do vírus SARS-CoV-2 a respeito da variante de Wuhan1 ancestral. Uma abordagem imunoinformática. 2022
A recombinant chimera contianing the C- and N- terminal moieties of the Nuclçsoide hydrolase (NH36) of Leishmania (L.) donovani in prophylaxis of mice agisnt Leishmania (L.) infantum infection. 2014
The One Health approach to visceral leishmaniasis. 2013
Vaccination against canine leishmaniosis in Brazil. Leishvet Symposium. WorldLeish 5 Congress. Porto de Galinhas, Pernambuco Brazil 2013
Vaccination with Nucleoside hydrolase (NH36) of L.(L.) donovani or its C-terminal portion (F3) in formulation with saponin prevents the deffective migration of Dendritic cells in murine experimental visceral leishmaniasis. 2013
Canine leishmaniosis: the disease, the problem and current approach to control and elimination. OIE-WSAVA symposium on Rabies and other disease risks from free-roaming dogs. 2013
The WSAVA One Health Committee: Positioning Companion Animals in Global Infectious Disease Surveillance. 2011
the WSAVA One Health Committee: Positioning Animals in Global infectious disease surveillance 2011
Mice vaccination with H3N8 inactivated by High Hydrostatic Pressure protect against experimental avian flu. 2011
Partial contribution of the B2 receptor of the kinin inflammation pathway in protection against murine visceral leishmaniasis by the C-terminal domain of Nucleoside hydrolase vaccine. 2011
Immunotherapy with the Leishmune®´s Nucleoside hydrolase DNA vaccine reduces infection and increases survival in a canine experimental model of visceral leishmaniasis. 2011
Increase of the adjuvant capability of Chiococca alba saponin by the increase of one sugar residue in the C-28 triterpene attached sugar chain. Effect on protection against visceral leishmaniasis. 2011
Cloning of the C-terminal Domain Peptides of Leishmania donovani Nucleoside Hydrolase (NH36) aiming the Identification of Antibody Epitopes.. 2011
Vaccination with the Leishmune®´s Nucleoside Hydrolase Maps the C-Terminal Domain as the Target of the Protective Immune Response 2010
Inactivation by Hydrostatic Pressure Preserves the Hemagglutinin and Neuraminidase Activities of the Avian Influenza Virus H3N8 2010
Comparison the Prophylactic Potential of the Nucleoside Hydrolase Genetic Vaccine on Visceral Leishmaniasis Administered in Mice through the Intramuscular or the Intranasal Route 2010
Selecionada para comunicação oral: Comparison of adjuvant potential of a QS-21-containing saponin and the CA3 and CA4 saponins from Chiococca alba (L.) Hitch in murine vaccination agsitn visceral leishmaniasis with the FML antigen 2010
VACCINATION WITH THE LEISHMUNE®´S NUCLEOSIDE HYDROLASE MAPS THE C-TERMINAL DOMAIN AS THE TARGET OF THE PROTECTIVE IMMUNE RESPONSE 2010
A decrease in the incidence of human and canine visceral leishmaniasis in endemic areas of Brazil following vaccination of dogs with Leishmune® 2009
Development of a Second-Generation Vaccine against Dengue 2009
. Identification of the Leishmania donovani Nucleoside Hydrolase (NH36)-Peptide Sequences Containing Epitopes Involved in Protective Immune Response against Murine Visceral Leishmaniasis. 2009
Comparison of the Immunogenicity and Efficacy of the Leishmune® Prophylactic and Therapeutic Vaccines against Canine Early Experimental Infection with Leishmania chagasi. 2009
The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine. 2008
Cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis. 2008
The Nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniaisis. 2008
Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL). 2008
Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis 2007
Vaccines for leishmaniasis in the fourthcoming 25 years 2007
Kinins generated aupon vaccination with the QS21 saponin-containing Leishmune(R) vaccine are partially responsibe for induction of protective immunity agaisnt visceral leishmaniasis 2007
Immunotherapy agasint canine visceral leishmanaisis with the saponin enriched Leishmune(R) vaccine 2007
Cross-protective efficacy of the prophylactic VR1012-NH36 Leishhmanaia-donovani DNA vaccine aginst cutaneous murine leishmaniasis by Leishmanaia amazonensis 2007
Structure-function studies of the novel CP05 saponin of Calliandra pulcherrima Benth adjuvant: assessment of monoterpene, glycidic fractions and triterpene in adjuvant function. 2006
Adjuvant effect of garlic extract with a DNA vaccine agasitn leishmania. 2006
Immunotherapy against visceral leishmaniasis with the nucleoside hidrolase-DNA vaccine of L donovani. Adjuvant effect of garlic EXtract. 2005
Phase I safety and immunogenicity trial of Leishmune ® in dogs of Brazilian endemic areas. 2005
The FML saponin vaccine against visceral leishmaniasis. Intranasal x subcutaneous administration in Balb/c mice. 2005
Leishmune ® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. 2005
Immunotherapy against experimental canine visceral leishmaniasis with the industrialized FML-vaccine Leishmune (1mg saponin adjuvant). 2005
A DNA vaccine agaisnt cutaneous and visceral leishmaniasis. 2005
Immunotherpay against canine visceral leishmaniaisis with the FML vaccine 2004
Cross-protective efficacy of a prophylactic Leishmania donovani-DNA vaccine against visceral and cutaneous murine leishmaniasis 2004
Safety and Immunogenicity of an inactivated subunit vaccine against canine visceral leishmaniaisis. 2004
The FML vaccine on immunoprophylaxis and immunotherapy of canine visceral leishmaniasis 2003
Evaluation of the Nucleoside hydrolase 36 of Leishmania donovani as a recombinant or DNA vaccine against Leishmanai mexicana 2003
Long-lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante,RN) 2002
Impact of canine control on Brazilian kala-azar 2001
BCG,IL12 and saponins in the FML-vaccine against visceral leishmaniasis in mice 2001
Human kala-azar upon blood transfusion. 2001
IL12 and QuilA saponin adjuvants in the FML-vaccine against experimental visceral leishmaniasis 2001
The FML vaccine against murine and canine visceral leishmaniasis 2001
The FML-vaccine: a second generation candidate for vacination againt murine and canine visceral leishmaniasis. 2001
The FMLvaccine: a second generation candidate for vaccination against murine and canine visceral leishmaniasis 2001
QS-21 saponin adjuvant in the FMLvaccine against experimental visceral leishmaniasis. 2001
Immunoterapeuthic effect of the FML vaccine against experimental visceral leishmaniasis in Balb/c mice 2000
Immunotherapeutic effect of the FML-saponin vaccine in one canine case of visceral leishmaniasis (Sao Gonçalo, RJ) 2000
Inibição da internalização de promastigotas de L.(L.) donovani em macrófagos peritoneais murinos pela glicoproteína GP36 2000
Human kala-azar upon blood transfusion 2000
The FML-ELISA assay in diagnosis of canine visceral leiahmaniasis in a recent outbreak at Araçatuba, SP. 2000
Comparative adjuvant effect of BCG and comercial saponins in the formulation of FML-vaccine against visceral leishmaniasis in mice 2000
Prevalencia de anticorpos anti-Leishmania chagasi através de técnicas sorológicas em amostras humans de General Carneiro, área urbana de Minas Gerais 2000
Prevalencia de anticorpos anti-Leishmania chagasi através de tecnicas sorologicas em amostras humanas de General Carneiro 2000
Analysisi of the adjuvant effect of Quillja brasiliensis saponins in the formulation of FML vaccine against visceral leiahmaniasis in mice 2000
Inhibition of Leishmania donovani promastigote internalization by the GP36 glycoprotein 2000
Occurrence of Leishmania donovani parasitemia in plasma of infected hamsters 2000
IL12 and saponin as adjuvants in the formulation of FML-vaccine against experimental visceral leishmaniasis 2000
Analysis of the hemolytic effect and in vivo toxicity of Quillaja brasiliensis saponins in the formulation of FML-vaccine against visceral leishmaniasis in mice 2000
Occurence of Leishmani donvani DNA in bone marrow of FML-seroreactive Brazilian Blood donors 1999
The FML vaccine against murine experimental visceral leishmaniasis. Comparison of the adjuvant effect of BCG and QuilA saponin 1999
Protective effect of the FML QuilA saponin vaccine against experimental canine kala-azar 1999
The FML elisa assay in serodiagnosis of canine visceral leishmaniasis of a recent outbreak in Araçatuba, Sao Paulo 1999
VACCINATION AGAINST CANINE KALA-AZAR WITH THE FML ANTIGEN AND rIEDEL dE HAEN SAPONIN IN AN ENDEMIC AREA (Sao Goncalo do Amaranto, RN) 1999
Cloning and characterization of Leishmania (L.) donovani inosine uridine nucleoside hydrolase 1999
Vacinacao contra o calazar canino com o antigeno FML de L. donovani e saponina no Rio Grande do Norte 1999
Vaccinataion Of Swiss Albino Mice Against Exprerimental Visceral Leishmaniasis With The Fml Antigen Of Leishmania Donovani 1998
Vacination Against Canine Kala-Azar With The Fml Antigen Of Leishmania Donovani And The Quila Saponin 1998
Investigação ultrasonografica e laboratorial em 7 pacientes soropositivos para leishmaniose atraves do FML-ELISA 1998
Vaccination against experimental kala-azar with the FML antigen of Leishmani donovani and QuilA saponin 1998
Vaccination against canine kala-azar with the FML antigen and Riedel De haen saponin in an endemic area (Sao Goncalo do Amaranto, RN) 1998
Ocurrence Of Leishmania Donovani Dna Inseroreactive Brazilian Blood Donors. 1997
Early Humoral Response In Mongrel Dog Vaccination With The Fml Antigen Of Leishmania Donovani In Combination With Saponin Adjuvants 1997
Prevalence Of Anti-Leishmania Donovani Antibodies Among Brazilian Blood Donors And Polytrasfused Hemodyalisis Patients.Correlation With Pcr 1997
Haemolytic activities of plant saponins and adjuvants Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani 1997
Comparative Ananlysisi Of The Adjuvant Activity Of The Abizia Saman Saponins On The Fml Antigen Of Leishmani Donovani 1997
Vaccination of balb/c mice with GP36 antigen of L. donovani and saponin 1997
The FMLELISA assay in diagnosis of canine visceral leishmaniasis 1997
Transmission Of Kala Azar By Blood Transfusion In Endemic Areas 1996
Exerimental murine Leishmania donovani infection: Imunoprotection by the fucose mannose ligand (FML). 1994
Surface glycoproteins of Leishmani donovani: GP36, the FML antigen present in pro and amastigotes is immunogenic for CB hamsters and recognized by human kala-azar antiserum 1991
Leishmania donovani (LD1S) Sudan glycoconjugates. Fatty acid composition and structure of LPPD glicidic moiety 1989
Leishmania donovani Lipopeptidephosphoglycan (LPPD) is not the major ligand for the promastigote internalization receptor on murine macrophages 1989
Leishmani donovani glycoconjugate ligands may be used for recognition and penetration of promastigotes into mouse macrophages 1988
Inhibition of Leishmania donovani promastigote internalization into murine macrophages by defined parasite glycoconjugate ligands 1988
Estudos dos gliccoconjugados de Leishmania donovani (LD1S) Sudan 1987
Publicações:
Minha Rede: